{"classes":[{"categories":[{"measurements":[{"comment":"NA: not estimable due to an insufficient number of participants with events.","groupId":"OG000","lowerLimit":"8.1","upperLimit":"NA","value":"16.6"},{"comment":"NA: not estimable due to an insufficient number of participants with events.","groupId":"OG001","lowerLimit":"1.5","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"DOIR is defined as the DOR based on lesions in brain (target, non-target lesions and new lesions, if applicable) and calculated from the time of first documented response of CR or PR to the date of the first documented disease progression in the brain or death due to any cause per modified RECIST 1.1 as assessed by BIRC neuro-radiologist.\n\nCR: Disappearance of all lesions with lymph nodes measuring \\< 10 mm. PR: At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ceritinib administered continuously through oral dosing at a dosage of 750 mg once daily in fasted state","id":"OG000","title":"Ceritinib"},{"description":"Pemetrexed plus cisplatin or carboplatin (based on Investigator's choice) for 4 cycles (Induction) followed by pemetrexed as single agent (Maintenance)","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. Patients with measurable brain disease and who had a baseline and at least one post-baseline scan, and a confirmed intracranial CR or PR","reportingStatus":"POSTED","timeFrame":"From first documented response to first documented disease progression in the brain or death, assessed up to approximately 34 months","title":"Duration of Intracranial Response (DOIR)","type":"SECONDARY","unitOfMeasure":"Months"}